Resources

The Alzheimer’s Show 2018

June 7, 2018

Re:Cognition Health Experts To Attend The Alzheimer’s Show 2018

Dr Emer MacSweeney, CEO, will be discussing new treatments for Alzheimer’s disease at the Alzheimer’s Show on Friday 8th June 2018
  • An estimated 850,000 people are living with dementia in the UK
  • This is expected to increase to 1 million by the year 2025 and to 2 million by 2050
  • Dementia is the only cause of death that is still on the rise

There has never been a more important time for clinical studies into this devastating disease

Re:Cognition Health is one of the most successful centers in the world for enrolling individuals onto clinical trials for Alzheimer’s disease. We are passionate about finding a cure for dementia.

Clinical trials are essential for advancing our understanding of medicine and improving the healthcare and quality of life for everyone affected by dementia and cognitive impairment.  By participating in an international clinical study, individuals can gain the potential personal benefit of early access to a new treatment, whilst also having an important global impact on our ability to treat a given condition.

New treatments now available in clinical trials, at no cost

Clinical trials provide early access to new Alzheimer’s drugs at no costs. Some drugs treat the symptoms whereas others target the underlying causes of the disease.

The ORY-2001 trial, which launches this month at Re:Cognition Health, will investigate the neuro-degenerative condition treated with an agent which acts as a DNA repair kit to restore memory and reverse behavioural changes, such as aggression and social avoidance.  The drug is designed to ‘reset’ the genes so they correctly control the behaviour of our cognitive brain cells, to improve memory, decrease agitation, improve social behaviour and reverse symptoms.

Dr MacSweeney comments: “The OR-2001 trial is a game-changing, novel approach which could benefit people with Alzheimer’s and any neuro-degenerative disease. It’s designed to repair damage to the genes that influence how nerves are going to behave. This is different to other drugs that work on the pathology of Alzheimer’s disease.”

Dr MacSweeney will be speaking at the Alzheimer’s Show:

8th June, 2018

Exhibitor Workshop Theatre

11:40am

 

9th June

Alzheimer’s Matters Theatre

12:30pm – Question time

Dr MacSweeney will be answering questions relating to Alzheimer’s disease on the panel

Dr Hannah Wright will be speaking at the Alzheimer’s Show:

9th June, 2018 

Alzheimer’s Matters Theatre

2:00pm